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AbstrACt
Objectives To evaluate the utility of different symptoms, 
alone or combined, presented to primary care for an adult 
brain tumour diagnosis.
Design and setting Matched case-control study, using 
the data from Clinical Practice Research Datalink (2000–
2014) from primary care consultations in the UK.
Method All presentations within 6 months of the index 
diagnosis date (cases) or equivalent (controls) were coded 
into 32 symptom groups. Sensitivity, specificity, positive 
predictive values (PPVs) and positive likelihood ratios were 
calculated for symptoms and combinations of symptoms 
with headache and cognitive features. Diagnostic odds 
ratios were calculated using conditional logistic regression, 
adjusted for age group, sex and Charlson comorbidity. 
Stratified analyses were performed for age group, sex and 
whether the tumour was of primary or secondary origin.
results We included 8,184 cases and 28,110 controls. 
Seizure had the highest PPV of 1.6% (95% CI 1.4% 
to 1.7%) followed by weakness 1.5% (1.3 to 1.7) and 
confusion 1.4% (1.3 to 1.5). Combining headache with 
other symptoms increased the PPV. For example, headache 
plus combined cognitive symptoms PPV 7.2% (6.0 to 8.6); 
plus weakness 4.4% (3.2 to 6.2), compared with headache 
alone PPV 0.1%. The diagnostic ORs were generally 
larger for patients <70 years; this was most marked for 
confusion, seizure and visual symptoms.
Conclusion We found seizure, weakness and confusion 
had relatively higher predictive values than many other 
symptoms. Headache on its own was a weak predictor but 
this was enhanced when combined with other symptoms 
especially in younger patients. Clinicians need to actively 
search for other neurological symptoms such as cognitive 
problems.
IntrODuCtIOn
Primary brain tumours are rare, so for every 
100 000 individuals one would only expect 
between to around 25 new cases in a year.1 2 A 
primary care practitioner working in a prac-
tice of around 10 000 patients would expect 
to diagnose between two to three patients 
with a brain tumour every year. Other more 
common cancers can metastasise to the brain, 
with similar symptoms1; patients may or may 
not have had the primary cancer previously 
diagnosed. Even where one exists, the doctor 
may not immediately make a connection 
depending on the length of the past cancer 
history and its pathological type. There is a 
very wide range of possible presenting symp-
toms depending on the location and size 
of the tumour and whether it is primary 
or secondary. Symptoms may be general 
strengths and limitations of this study
 ► Largest study to examine systematically a wide 
range of symptoms for patients with both primary 
and secondary brain tumours in primary care.
 ► Greater power has enabled us to look into symptom 
combinations both acutely and within a 6-month 
window, as well as stratifying by age group and 
gender.
 ► Results only apply to patients presenting in primary 
care and are not generalisable to all brain tumours 
as we have not included patients who first present 
to the emergency department.
 ► For some symptoms and combinations of symptoms 
we had to aggregate symptom groups to increase 
statistical power.
 ► We can only examine what symptoms were coded 
by general practitioners rather than what symptoms 
were actually discussed during the consultation and 
any clinical signs that were elicited.
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non-specific rather than focal neurological and may or 
may not suggest the correct diagnosis.
General practitioners can find it difficult to distinguish 
which patients should be referred for rapid assessment 
because of a suspicion of a brain tumour based on symp-
toms alone, rather than through a less acute diagnostic 
pathway. Additionally, patients may present for the first 
time directly as an emergency to hospital, often with a 
seizure or acute weakness (paralysis), thereby bypassing 
primary care altogether.3 Some of these patients will have 
previously consulted with their general practitioner with 
non-specific symptoms possibly related to their brain 
tumour.
A previous descriptive study examining patients’ symp-
toms presenting in primary care listed the most common 
presentations and their predictive values.4 A systematic 
review of cancer of the brain and central nervous system 
identified six studies with 159 938 patients.5 However, 
only two of these six studies examined adult brain 
tumours, with one study being a case cohort study of 
headache with follow-up to determine the risk of being 
subsequently diagnosed as a brain tumour.6 In the case 
control study, the seven most common features associ-
ated with brain tumours were (in order of increasing 
positive predictive values (PPV)): motor loss (0.026%), 
visual disorder (0.035%), memory loss (0.036%), head-
ache (0.09%), generalised weakness (0.14%), confusion 
(0.20%) and new onset seizure (1.2%). There was some 
evidence that predictive values were greater for patients 
aged 60 to 69 years.4 The case cohort study found a 
slightly higher risk of a brain tumour for headache, with 
the PPV in that study ranging from 0.08% to 0.28% below 
and above 50 years of age, suggesting that older age may 
be more predictive.6
We have previously reported, using data from the 
National Audit of Cancer diagnosis in Primary Care, that 
patients presenting with headaches, behavioural/cogni-
tive changes or other/non-specific symptoms attended 
their general practitioner (GP) more frequently before 
referral. Isolated headache and memory loss were asso-
ciated with a much slower diagnostic pathway, mainly 
due to delay in referral to a specialist.7 A mathematical 
model of tumour growth suggests that delay to the start of 
radiotherapy has a possible deleterious effect on patient 
survival in patients with glioblastoma, the most aggressive 
type of tumour.8 However, there is almost no evidence 
for this in one observational study9 and more aggressive 
tumours may present more rapidly due to sudden onset 
of severe symptoms and in turn have worse survival.
In this paper, we re-examine the diagnostic utilities of 
a wide range of symptoms for patients who present with 
brain tumours, compared with a control population, 
in a primary care setting across the UK. We specifically 
focussed on whether combinations of features for head-
ache and cognitive symptoms can improve diagnosis, 
whether the predictive value of clinical features differ 
by sex, age sub-groups and whether the diagnosis was a 
primary or secondary tumour.
MAterIAl AnD MethODs
study design and selection of cases and controls
We used electronic patient record data from the UK’s 
Clinical Practice Research Datalink (CPRD), formerly 
known as the General Practice Research Database. CPRD 
contains anonymised primary care medical records from 
around 680 UK general practices, representing 8.8% of 
the entire UK population (https://www. cprd. com/).
These data comprise information routinely recorded 
by GPs during their consultations with patients. Personal 
information is collected, as well as clinical events such as 
symptoms, diagnoses, prescriptions, treatment and death. 
Information is stored using Read codes – the standard 
clinical terminology within UK primary care.10
Cases were defined as patients aged 18 and over with 
a record of either a primary or secondary brain tumour, 
diagnosed between 1st January 2000 and 31st December 
2014. We excluded meningiomas because of their differ-
ence in prognosis and presentation. We defined cases of 
brain tumours by using a large number of relevant Read 
codes mapped to the CPRD medcodes (see online supple-
mentary appendix I for the complete list). The index date 
of diagnosis was then taken as the earliest date with one 
of these specific brain tumour codes in the CPRD files.
We used a matched case-control study design so that 
controls were matched to cases where possible by year 
of birth, sex and practice and had the same index date 
allocated as their respective case. To enhance power, we 
used a 1:4 case to control ratio. Patients had to come from 
a practice with at least 6 months of up-to-standard data 
before a diagnosis. We excluded any cases and controls, 
who had no GP visit for 6 months prior to the index date 
to remove ‘ghost’ patients.
symptoms
We created symptom dictionaries based on a dual top 
down and bottom up approach using clinical knowledge 
of phenomenology for the former and frequency of 
symptom presentations in the tumour case series for the 
latter. We used the first four digits of the Read codes to 
identify potential symptoms related to a tumour and then 
one of our clinical researchers (KZ), classified these into 
appropriate symptom groups, as the Read code system 
allows the same phenomenology to be coded in more 
than one way. Symptoms were grouped according to simi-
larity (such as smell and taste). All the symptom groups 
were then checked again by several other members of the 
team, including an academic general practitioner and 
clinical epidemiologist (YBS, WHa, MO). This procedure 
is in line with best practice for generating code lists using 
electronic health records.11
In some cases, we aggregated individual symptoms into 
larger groups due to small numbers (which would have 
produced very imprecise estimates) as long as this made 
clinical sense. For example the broad category of visual 
symptoms included diplopia, loss of vision, deteriorating 
vision, patient concerned about eyesight, has a squint, 
other binocular vision disorders, etc. This generated 32 
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independent symptom groups of which 23 were neuro-
logically-related symptoms (see online supplementary 
appendix II). To examine consistency, we compared our 
Read codes for some symptom groups (eg, weight loss, 
vomiting, etc) with those previously derived from another 
cancer diagnostic study (led by WHa)12 to check for 
completeness and, if necessary, appended any additional 
codes that we had missed very occasionally.
As our previous work7 had already highlighted the diag-
nostic delays with headache and cognitive problems, we 
examined the utility of these symptoms in combination 
with other symptoms. For these analyses, we aggregated 
the original cognition variable with presentations labelled 
‘concentration’ and ‘confusion’ to create a broader 
‘cognitive’ variable to enhance our statistical power to 
look at other combinations. We looked at combinations 
of symptoms that appeared together with headache and 
cognitive complaints acutely within 1 month or that 
appeared to be independent temporally but may have 
been related to the same underlying cause that is, brain 
tumour, within a 6-month time window prior to the index 
date (see below for further details about the different time 
window cut-offs that we tried initially). We called these 
combinations as headache or cognitive ‘plus’ group if the 
patient had either headache or cognitive problems with 
another neurological-related symptom(s). If the patient 
did not have any other neurological related symptoms, we 
treated them as ‘headache only’ or ‘cognitive only’.
Other covariates
We also derived the Charlson Index Score13 as other 
comorbidities may be used by clinicians to explain the 
presence or absence of some symptoms, which may result 
in diagnostic confusion and delay in diagnosis. Alterna-
tively, a prior history of a non-brain tumour cancer may 
lower a doctor’s threshold for suspicion that a headache 
may relate to metastatic disease. The Charlson Index is 
constructed by identifying 17 categories of comorbid 
disease. Each disease is based on their association with 
1 year all-cause mortality to produce a total prognostic 
score. We only used comorbidities prior to the index date 
for cases (and equivalent date for controls) so that cases 
could have a Charlson Score of zero.
statistical analyses
Our aim was to derive the diagnostic utilities of specific 
symptoms or combination of symptoms for patients 
who presented to general practice that is, the diagnostic 
odds ratio (OR) of having a brain tumour conditional 
on seeking care. We adjusted for sex and age in 10 year 
age-bands as having excluded ‘ghost patients’ there 
were some imbalances between cases and controls. We 
produced basic descriptive data using summary statistics 
and regression or X2 tests. We calculated diagnostic utili-
ties (sensitivity, specificity, positive predictive values (PPV) 
and positive likelihood ratio (PLR) which is defined as 
sensitivity/1-specificity, or the frequency of symptoms in 
cases divided by frequency of symptoms in controls. We 
initially looked at a variety of different latency periods 
prior to the index date: 1 month, 3 months, 6 months 
and 1 year, as we were not certain of the optimum retro-
spective time-period to evaluate.
Because of our sampling strategy (four controls to 
one case), the crude PPV from the two by two table will 
be grossly overestimated as we have only taken a small 
random sample of all potential controls and hence our 
incidence of brain tumours is artefactually elevated, 
by design, at 20%. We therefore weighted the control 
samples by the actual denominator in CPRD data set in 
each combination of age (less than 40, 40 to 49, 50 to 59, 
60 to 69, 70 to 79, 80 and over) and sex categories. Cases 
have a default weight of 1 as we took all cases rather than 
a sample. To test for the strength of association between 
symptoms and case/control status and to produce a 
single summary indicator, we used conditional logistic 
regression and computed diagnostic ORs (DORs),14 95% 
CIs and p values after adjustment for gender, age group 
and Charlson Index. Stata 15 was used for the analysis.
We repeated our analyses using sex and age strata 
(<60, 60 to 69, ≥70 years), as in a previous publication,4 
to examine for possible heterogeneity of associations. To 
examine whether clinical presentation profiles differed 
by pathology, we also undertook a subgroup analysis strat-
ifying the tumours into primary and secondary and tested 
for heterogeneity between the DORs by symptoms using 
multinomial logistic regression.
Patient and public involvement
No patients were involved in the design, analysis or 
reporting of this work. However, carers of patients attended 
a meeting where preliminary results were presented and 
provided helpful comments on our findings.
results
In total 8184 cases and 28 110 controls were included 
in our study after excluding 98 cases (1.2%) and 5240 
controls (18.6%) without a GP visit 6 months prior to the 
diagnosis date. This comprised of 4454 (54.4%) primary 
malignant brain tumours and 3730 (45.6%) secondary 
brain tumours. The age and gender distribution for cases 
and controls are shown in table 1 and was very similar due 
to the matching process. Cases showed higher Charlson 
Index Score than controls.
Table 2 shows the frequency of symptoms in cases and 
controls in the 6 months before diagnosis. We chose this 
time-period rather than 1 year as the increase in frequency 
of symptoms was far greater for controls (approximately 
doubling) than cases over this period. This highlights the 
temporal clustering of symptoms in the 6 months prior to 
diagnosis rather than a simple linear increase due to the 
longer observation period. Six months compared with 3 
months had greater sensitivity, so was also considered to 
be more useful and is consistent with the natural history 
of primary brain tumours,15 though our sample also 
includes secondary tumours.
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Table 1 Sociodemographic characteristics in cases and 
controls
Brain tumour status
Case Control
(n=8184) (%) (n=28 110) (%)
Gender
  Male 4113 (50.3) 13 257 (47.2)
  Female 4071 (49.7) 14 853 (52.8)
  Total 8184 (100) 28 110 (100)
Age at the event
  18–39 462 (5.7) 1375 (4.9)
  40–49 687 (8.4) 2084 (7.4)
  50–59 1438 (17.6) 4639 (16.5)
  60–69 2326 (28.4) 8123 (28.9)
  70–79 2148 (26.3) 7812 (27.8)
  >80 1123 (13.7) 4077 (14.5)
  Total 8184 (100) 28 110 (100)
Charlson index score
  0 3045 (37.2) 16 530 (58.8)
  1 1253 (15.3) 5194 (18.5)
  2 1753 (21.4) 3083 (11.0)
  3 850 (10.4) 1402 (5.00)
  4+ 1283 (15.7) 1901 (6.8)
  Total 8184 (100) 28 110 (100)
We found that 23 of the 32 symptom groups differed 
between cases and controls (only these are shown in 
table 2). The most sensitive neurological symptom 
groups for cases were headache and ataxia (gait-related) 
symptoms, though non-neurological symptoms included 
fatigue and cough, perhaps reflecting an underlying 
different primary malignancy. The three least specific 
symptoms (highest false-positive rate) were cough, 
depression and fatigue. From a diagnostic perspective 
however, the largest positive predictive values (>1.0%) 
and PLRs were seen for seizure, followed by weakness and 
confusion, but even then their predictive values ranged 
from 1.4% to 1.6%, highlighting that the vast majority of 
patients with these features will transpire not to have a 
brain tumour.
Both headache and cognitive symptoms were predic-
tive but with more modest effects, so that headache, 
though the most sensitive feature only had a PPV of 
0.2% (ie, brain tumour found in 2 per 1000 patients with 
this symptom). Further exploration of these symptoms 
showed that the diagnostic utilities were enhanced when 
looking at the headache/cognitive plus groups (table 3) 
as compared with headache or cognitive only symptoms. 
While symptom combinations were more predictive when 
presenting together within a month, the predictive values 
were only slightly larger than when the longer time window 
of 6 months was taken. The two strongest combination of 
symptom combinations were headache plus the broader 
range of cognitive symptoms (PPV 7.2%) and cognitive 
plus weakness (PPV 9.6%).
The results from our conditional logistic models found 
that for most tumour-related symptoms, there were no 
sex differences, but depression, fatigue, seizure and head-
ache were more diagnostically useful in men (male and 
female DORs depression 2.77 vs 1.87, p value for effect 
modification=0.004; fatigue 6.37 vs 4.61, p value for effect 
modification=0.004; seizure 59.4 vs 27.0, p value for effect 
modification=0.02; headache only 7.08 vs 4.88, p value for 
effect modification=0.006) while sleep disturbance was a 
stronger predictor in women (1.54 vs 2.38, p value for 
effect modification=0.007). When we stratified the sample 
into three age groups (<60, 60 to 69, ≥70 years), we found 
evidence of differences in the predictive value of some 
symptoms by age group (see table 4). In all cases, other 
than for depression, symptoms among patients younger 
than 70 years showed greater diagnostic ORs. This pattern 
was particularly marked for confusion, where the largest 
DOR was seen in the 60 to 69 year age group, and for 
seizure andvisual symptoms where patients <70 years had 
much higher DORs than older patients though for visual 
symptoms this was driven by the <60 year age group.
Our multinomial logistic models found that some 
symptoms were equally predictive for both primary and 
secondary tumours (eg, headache DOR 21.2 and 21.5 for 
primary and secondary tumours, respectively), cognitive 
symptoms were more common for primary tumours (DOR 
17.6 vs 6.8 for primary and secondary tumours, respec-
tively, p value for heterogeneity <0.001) and generalised 
symptoms such as lack of appetite were more common 
in secondary tumours (DOR 3.6 vs 9.0 for primary and 
secondary tumours respectively, p value for heterogeneity 
<0.001).
DIsCussIOn
We have examined the value of clinical presentations in 
primary care to aid the clinician in suspecting the diag-
nosis of a brain tumour. Like previous studies,4 5 7 we 
find the obvious clinical features such as seizures, weak-
ness and other cognitive problems were the most predic-
tive findings. However, the data make it clear that no 
feature alone is very predictive in absolute terms. The 
vast majority of patients with such features do not have 
a brain tumour (false-positive) though they may have 
another important pathology. In addition, we note that 
several non-specific symptoms, such as cough, fatigue 
and appetite problems are also more common and this 
is most likely related to our inclusion of secondary brain 
tumours, that are normally excluded from such studies. 
Interestingly, while headache was equally predictive for 
both primary and secondary tumours, the broader cate-
gory of cognitive symptoms were more predictive for 
primary tumours, which we speculate might reflect the 
infiltrative nature and location of gliomas16 compared 
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Table 2 Frequency of symptoms that differed between cases and controls in 6 months before diagnosis
Brain tumour status
PPV* (%) PLR* (95% CI)
Case Control
(n=8184) (n=28 110)
Number with 
symptoms Sensitivity
Number with 
symptoms Specificity
Anxiety 360 (4.4) 458 (98.4) 0.1 2.06 (1.86 to 2.28)
Appetite 125 (1.5) 72 (99.7) 0.3 8.40 (7.06 to 10.0)
Ataxia 624 (7.6) 351 (98.8) 0.4 9.42 (8.74 to 10.2)
Cognition 323 (3.9) 99 (99.6) 0.7 18.4 (16.5 to 20.4)
Concentration 11 (0.1) 3 (100.0) 0.2 4.49 (2.49 to 8.12)
Confusion 474 (5.8) 92 (99.7) 1.4 36.9 (33.8 to 40.3)
Consciousness 148 (1.8) 112 (99.6) 0.3 6.79 (5.79 to 7.95)
Cough 852 (10.4) 2010 (92.8) 0.1 1.73 (1.62 to 1.84)
Depression 438 (5.4) 699 (97.5) 0.1 1.84 (1.68 to 2.01)
Dizziness 310 (3.8) 219 (99.2) 0.2 5.93 (2.53 to 6.61)
Falls 318 (3.9) 343 (98.8) 0.2 5.73 (5.15 to 6.37)
Fatigue 1005 (12.3) 699 (97.5) 0.2 5.72 (5.40 to 6.06)
Headache 1163 (14.2) 518 (98.2) 0.2 5.70 (5.40 to 6.01)
Nausea 604 (7.4) 353 (98.7) 0.2 6.22 (5.77 to 6.72)
Pain 305 (3.7) 531 (98.1) 0.1 2.51 (2.25 to 2.80)
Seizure 489 (6.0) 46 (99.8) 1.6 40.8 (37.5 to 44.5)
Sensation 252 (3.1) 190 (99.3) 0.2 5.11 (4.53 to 5.76)
Sleep 286 (3.5) 466 (98.3) 0.1 2.70 (2.41 to 3.03)
Speech 382 (4.7) 87 (99.7) 0.8 19.7 (17.9 to 21.8)
Vertigo 84 (1.0) 100 (99.6) 0.1 3.66 (2.96 to 4.53)
Visual 327 (4.0) 163 (99.4) 0.5 12.3 (11.1 to 13.7)
Weakness 303 (3.7) 37 (99.9) 1.5 39.4 (35.3 to 43.9)
Weight 161 (2.0) 163 (99.4) 0.2 3.94 (3.38 to 4.60)
*Calculated after weighting for population sampling.
PLR, positive likelihood ratio; PPV, positive predictive value.
with metastatic disease,17though it is not obvious why this 
may be the case.
We explored whether combinations of symptom presen-
tation would enhance predictive value for two common, 
but non-specific presentations of headache and cognitive 
complaints. They did indeed enhance prediction but with 
the expected cost of lower sensitivity. In particular, we 
think the concept of ‘headache plus and cognitive plus’ 
is useful as evidenced by the better PPV and PLRs. Symp-
toms that occurred closely together (within 1 month) had 
stronger predictive value but widening the time window 
to 6 months was only a little weaker and captures more 
cases.
Simple demographic factors are also helpful in raising 
clinical suspicion. For example, headaches in men were 
more predictive than in women and younger age (<70 
years) was in general associated with higher predictive 
values for most features except depression, presumably 
because with increasing age there is an increase in other 
comorbid conditions18 providing alternative reasons for 
the symptoms.
strengths and limitations
This is the largest study so far to examine systematically 
a wide range of symptoms for patients with both primary 
and secondary brain tumours as this more realistically 
reflects the clinical dilemma facing GPs. While the data 
come from the UK, they are likely to be generalisable to 
other high income primary care settings. We excluded 
meningiomas as most are detected asymptomatically in 
imaging for other indications, tend to be more benign 
and slow growing with a more insidious development of 
clinical symptoms. Our greater power has enabled us to 
look into symptom combinations both acutely and within 
a 6-month window, as well as stratifying by age group and 
gender. However, several important limitations remain. 
It is important that these results only apply to patients 
presenting in primary care and are not generalisable to 
copyright.
 o
n
 O
ctober 29, 2019 at University of Exeter. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029686 on 30 August 2019. Downloaded from 
6 Ozawa M, et al. BMJ Open 2019;9:e029686. doi:10.1136/bmjopen-2019-029686
Open access 
Table 3 Frequency of symptom combinations for headache and cognitive features in 1 or 6 months before diagnosis
Brain tumour status
PPV††(%) PLR (95% CI)
Case (n=8184) Control (n=28 110)
Number with 
symptoms Sensitivity
Number with 
symptoms Specificity
Headache
  Headache plus (1 month) 476 (5.8) 81 (99.7) 0.7 18.1 (16.6 to 19.8)
  Headache only (1 month) 687 (8.4) 437 (98.4) 0.1 3.92 (3.65 to 4.21)
  Headache plus (6 months) 569 (7.0) 116 (99.6) 0.6 16.3 (15.0 to 17.6)
  Headache only (6 months) 594 (7.3) 402 (98.6) 0.1 3.57 (3.30 to 3.86)
  Headache +depression (6 
months)
83 (1.0) 32 (99.9) 0.4 9.90 (7.99 to 12.3)
  Headache +cognition (6 
months)
47 (0.6) 2 (100.0) 5.9 165 (123 to 221)
  Headache +weakness (6 
months)
35 (0.4) 1 (100.0) 4.4 122 (87 to 171)
  Headache +nausea (6 months) 167 (2.0) 11 (100.0) 2.0 55 (47 to 64)
Cognitive*
  Cognitive plus (1 month) 325 (4.0) 48 (99.8) 1.5 39 (35 to 44)
  Cognitive only (1 month) 435 (5.3) 140 (99.5) 0.7 18.9 (17.2 to 20.7)
  Cognitive plus (6 months) 379 (4.6) 69 (99.8) 1.2 32.0 (29.0 to 35.3)
  Cognitive only (6 months) 381 (4.7) 119 (99.6) 0.7 19.6 (17.8 to 21.7)
  Cognitive +depression (6 
months)
62 (0.8) 20 (99.9) 0.5 12.9 (10.1 to 16.6)
  Cognitive +headache (6 
months)
111 (1.4) 4 (100.0) 7.2 205 (169 to 249)
  Cognitive +weakness (6 
months)
19 (0.2) 1 (100.0) 9.6 282 (176 to 451)
  Cognitive +nausea (6 months) 60 (0.7) 5 (100.0) 3.5 96 (74 to 124)
*This cognitive variable is a composite of cognition, concentration and confusion symptoms.
† Calculated after weighting for population sampling.
PLR, positive likelihood ratio; PPV, positive predictive value.
all brain tumours as we have not included patients who 
first present to the emergency department. While we 
have a larger number of tumours, for some symptoms 
and for the combination of symptoms we had to aggre-
gate symptom groups to increase our numbers. Even 
then some of our estimates are imprecise due to small 
numbers, especially in the control sample. We can only 
examine what symptoms were coded by GPs rather 
than what symptoms were actually discussed during 
the consultation. For example, hardly any patients had 
early morning headache recorded. It may be that GPs 
did not ask about this specific feature or they did, but it 
was absent, hence not coded, or they did but they simply 
coded it as a generic headache rather than use the specific 
early morning headache code.19 Similarly, a GP may have 
elicited several symptoms but only chose to code some, 
probably the most worrying feature where they suspect 
serious pathology and there is evidence that for haema-
turia, jaundice and abdominal pain 38% of these feature 
were missing from Read codes but hidden in free text.20 
If combinations of features are less likely to be coded and 
occur more frequently in case than controls, then this 
sort of misclassification would result in an underestima-
tion of the value of combined features. We did not try to 
look at data on clinical examination as this is known to 
be under-recorded in this setting.4 We undertook many 
hypothesis tests including tests for interaction so one 
should be cautious over some of the ‘statistically signif-
icant’ results, especially within the 0.01 to 0.05 range as 
these may simply reflect a type I chance error.
We believe that this work has the following implications. 
To enhance the chance of earlier suspicion and hence 
referral of patients with possible brain tumours, GPs 
must actively question patients about other neurological 
related symptoms that may not emerge from the initial 
presenting history especially for headache and cognitive 
presentations (headache and cognitive plus). Referral 
threshold should be lower where there is a past history 
of malignancy as almost half of our cases were secondary 
tumours. Non-specific cancer-related features, such as 
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Table 4 Diagnostic Odds Ratios* for individual clinical 
presentations stratified by age group (<60, 60 to 69, ≥70 
years) that showed evidence of effect modification
Symptom
Diagnostic ORs
P value 
for effect 
modification
Age group (years)
<60 60–69 ≥70
Anxiety 1.44 1.39 1.24 0.02
Ataxia 8.28 9.57 5.16 0.004
Confusion 43.9 96.4 12.6 <0.001
Consciousness 6.93 7.03 3.1 0.02
Depression 1.5 2.65 2.77 <0.001
Headache 11.3 9.15 6.08 <0.001
Nausea 6.86 5.82 3.19 <0.001
Seizure 89.3 70 14.5 <0.001
Sleep 2.72 1.48 1.78 0.03
Visual 22.8 5.11 4.9 <0.001
*Models adjusted for age group, gender and Charlson 
Comorbidity Index.
lack of appetite, may also be helpful even when there 
is no known past history. There is a need to review any 
past consultations in the last 1 to 6 months, that may not 
initially have been considered to be temporally related, 
for symptom combinations that might suggest a common 
pathological cause rather than assuming multiple pathol-
ogies are present (this principle is known as Occam’s 
razor). Symptoms in younger patients may have greater 
significance, though one must be careful in assuming that 
symptoms in older patients are always due to comorbid-
ities. Recent qualitative research highlights that patients 
often experience multiple subtle changes (‘you weren’t 
quite yourself’, ‘brain not working properly’) that may be 
more noticed by a partner.21
Despite all the above, diagnostic information will result 
in many false-positive referrals, highlighting the need for 
better methods to help GPs screen possible referrals. We 
have recently demonstrated that a simple semantic verbal 
fluency task, that is, name as many animals as possible 
within a minute, is helpful in differentiating patients with 
headache and a brain tumour from those with headache, 
but without a brain tumour, presumably because of subtle 
cognitive deficits that the patient and/or carer may not 
have noticed (Zienius et al personal communication). 
Other options to support assessment of brain tumour 
risk could include biomarkers, either from blood, saliva 
or breath.22 These have the potential to eventually be 
done rapidly, assuming they are not overly expensive. 
Future research should examine the addition of such 
tests either in primary care and the emergency depart-
ment to enhance diagnostic utility with the ultimate aim 
of producing an automated diagnostic algorithm that 
would enable better risk stratification of patients that 
need urgent assessment.
In conclusion, we have shown how difficult it is to for 
GPs to accurately suspect brain tumours and if referral 
is based solely on the presence or absence of the various 
symptoms reported in this study then the majority of 
patients will turn out not to have a brain tumour. The 
predictive value of headache and cognitive symptoms can 
be enhanced by considering a wider array of symptoms 
(‘headache or cognitive plus’) in the 6 months prior to 
diagnosis and as well as the age of the patient. Newer 
tests are required to help GPs enhance their diagnostic 
abilities.
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